Comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'

被引：2
|
作者：
Tougeron, D. [1 ]
Laurent-Puig, P. [2 ]
Zaanan, A. [2 ,3 ]
机构：
[1] Univ Poitiers Hosp, Dept Gastroenterol, Poitiers, France
[2] INSERM, UMR S775, Paris, France
[3] European Georges Pompidou Univ Hosp, AP HP, Dept Gastroenterol & Digest Oncol, Paris, France
来源：
BRITISH JOURNAL OF CANCER | 2014年 / 111卷 / 12期
关键词：
CIRCULATING MUTANT-DNA; ANTI-EGFR THERAPY; K-RAS MUTATIONS; ACQUIRED-RESISTANCE; CETUXIMAB; PCR;
D O I：
10.1038/bjc.2014.114
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2379 / 2380
页数：3
相关论文
共 50 条
  • [21] A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer
    Do, Khanh
    Cao, Liang
    Kang, Zhigang
    Turkbey, Baris
    Lindenberg, Maria L.
    Larkins, Erin
    Holkova, Beata
    Steinberg, Seth M.
    Raffeld, Mark
    Peer, Cody J.
    Figg, William D.
    Eugeni, Michelle
    Jacobs, Paula
    Choyke, Peter
    Wright, John J.
    Doroshow, James H.
    Kummar, Shivaani
    CLINICAL COLORECTAL CANCER, 2015, 14 (03) : 154 - 161
  • [22] Noncoding RNA Profile in Reovirus Treated KRAS-Mutated Colorectal Cancer Patients
    Saperstein, Rafael
    Goel, Sanjay
    Maitra, Radhashree
    DISEASES, 2023, 11 (04)
  • [23] QUANTITATIVE MEASUREMENT OF KRAS MUTATED ALLELES IN PLASMA AS PROGNOSTIC MARKER IN METASTATIC KRAS MUTANT COLORECTAL CANCER
    Spindler, K.
    Pallisgaard, N.
    Andersen, R.
    Jakobsen, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 530 - 531
  • [24] Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in KRAS-mutated colorectal cancer
    Ghosh, Susmita
    Fan, Fan
    Powell, Reid
    Park, Yong Sung
    Stephan, Clifford
    Kopetz, E. Scott
    Ellis, Lee M.
    Bhattacharya, Rajat
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [25] Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma
    Spindler, Karen-Lise G.
    Sorensen, Morten M.
    Pallisgaard, Niels
    Andersen, Rikke F.
    Havelund, Birgitte M.
    Ploen, John
    Lassen, Ulrik
    Jakobsen, Anders K. M.
    ACTA ONCOLOGICA, 2013, 52 (05) : 963 - 970
  • [26] Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial
    Samalin, E.
    Bouche, O.
    Thezenas, S.
    Francois, E.
    Adenis, A.
    Bennouna, J.
    Taieb, J.
    Desseigne, F.
    Seitz, J. F.
    Conroy, T.
    Galais, M. P.
    Assenat, E.
    Crapez, E.
    Poujol, S.
    Bibeau, F.
    Boissiere, F.
    Laurent-Puig, P.
    Ychou, M.
    Mazard, T.
    BRITISH JOURNAL OF CANCER, 2014, 110 (05) : 1148 - 1154
  • [27] Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial
    E Samalin
    O Bouché
    S Thézenas
    E Francois
    A Adenis
    J Bennouna
    J Taieb
    F Desseigne
    J F Seitz
    T Conroy
    M P Galais
    E Assenat
    E Crapez
    S Poujol
    F Bibeau
    F Boissière
    P Laurent-Puig
    M Ychou
    T Mazard
    British Journal of Cancer, 2014, 110 : 1148 - 1154
  • [28] Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
    Macarulla, T.
    Cervantes, A.
    Tabernero, J.
    Rosello, S.
    Van Cutsem, E.
    Tejpar, S.
    Prenen, H.
    Martinelli, E.
    Troiani, T.
    Laffranchi, B.
    Jego, V.
    von Richter, O.
    Ciardiello, F.
    BRITISH JOURNAL OF CANCER, 2015, 112 (12) : 1874 - 1881
  • [29] Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
    T Macarulla
    A Cervantes
    J Tabernero
    S Roselló
    E Van Cutsem
    S Tejpar
    H Prenen
    E Martinelli
    T Troiani
    B Laffranchi
    V Jego
    O von Richter
    F Ciardiello
    British Journal of Cancer, 2015, 112 : 1874 - 1881
  • [30] Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer
    Sandhu, Jaideep
    Wang, Chongkai
    Fakih, Marwan
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (02): : 116 - 119
12345